{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T11:29:31Z","timestamp":1749209371288,"version":"3.40.5"},"posted":{"date-parts":[[2023,12,28]]},"group-title":"In Review","reference-count":111,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T00:00:00Z","timestamp":1703721600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,10,21]]},"abstract":"<title>Abstract<\/title>\n        <p><bold>Background<\/bold>: Major Depressive Disorder (MDD) is a leading cause of disability worldwide across domains of health and cognition, affecting overall quality of life. Approximately one third of individuals with depression do not fully respond to treatments (e.g., conventional antidepressants, psychotherapy) and alternative strategies are needed. Recent early phase trials suggest psilocybin may be a safe and efficacious intervention with rapid-acting antidepressant properties. Psilocybin is thought to exert therapeutic benefits by altering brain network connectivity and inducing neuroplastic changes that endure for weeks post-treatment. Although early clinical results are encouraging, psilocybin\u2019s acute neurobiological effects on neuroplasticity have not been fully investigated. <bold>W<\/bold>e aim to examine for the first time how psilocybin acutely (intraday) and subacutely (weeks) alters functional brain networks implicated in depression.\n<bold>Methods<\/bold>: Thirty-six participants diagnosed with MDD or Persistent Depressive Disorder (PDD) will be recruited from a tertiary mood disorders clinic and undergo 1:1 randomization into either an experimental or control arm. Participants will be given either 25 mg psilocybin or active placebo (100 mg niacin) for the first treatment. Three weeks later, those in the control arm will cross over and all participants will receive 25 mg psilocybin. We will investigate whether treatments are associated with changes in arterial spin labelling and blood oxygenation level dependent contrast neuroimaging assessments at acute and subacute timepoints. Primary outcomes include testing whether psilocybin demonstrates acute changes in 1) cerebral blood flow and 2) functional brain activity in networks associated with mood regulation and depression when compared to placebo. Secondary outcomes include changes in MADRS score over time compared to placebo, and changes across complementary clinical psychiatric, cognitive, and functional scales from baseline to final follow-up. Serum peripheral neurotrophic and inflammatory biomarkers will be collected at baseline to examine relationships with clinical response, and neuroimaging measures.\n<bold>Discussion<\/bold>: This study will investigate the acute and additive subacute neuroplastic effects of psilocybin on brain networks affected by depression using advanced serial neuroimaging methods. Results will improve our understanding of psilocybin\u2019s antidepressant mechanisms versus placebo response and whether biological measures of brain function can provide early predictors of treatment response.\nTrial registration: ClinicalTrials.gov Identifier: NCT06072898. Registered on 6 October 2023.<\/p>","DOI":"10.21203\/rs.3.rs-3474764\/v1","type":"posted-content","created":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T12:18:51Z","timestamp":1703765931000},"source":"Crossref","is-referenced-by-count":1,"title":["Engaging Mood Brain Circuits with Psilocybin (EMBRACE): a study protocol for a randomized, proof-of-principle, placebo-controlled and crossover, neuroimaging trial in depression"],"prefix":"10.21203","author":[{"given":"Joshua M","family":"Poulin","sequence":"first","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory E","family":"Bigford","sequence":"additional","affiliation":[{"name":"University of Miami"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Krista L","family":"Lanctot","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Giacobbe","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayal","family":"Schaffer","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Sinyor","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer S","family":"Rabin","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Masellis","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Singnurkar","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7014-3280","authenticated-orcid":false,"given":"Christopher B","family":"Pople","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nir","family":"Lipsman","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J","family":"MacIntosh","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sean M","family":"Nestor","sequence":"additional","affiliation":[{"name":"Sunnybrook and Women's College Health Sciences Centre: Sunnybrook Health Sciences Centre"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","unstructured":"Global Burden of Disease Study. 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800."},{"issue":"4","key":"ref2","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1001\/jamapsychiatry.2014.2502","article-title":"Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis","volume":"72","author":"Walker ER","year":"2015","unstructured":"Walker ER, McGee RE, Druss BG. Mortality in mental disorders and global disease burden implications: a systematic review and meta-analysis. JAMA Psychiatry. 2015;72(4):334\u201341.","journal-title":"JAMA Psychiatry"},{"issue":"9505","key":"ref3","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0140-6736(06)67964-6","article-title":"Recent developments and current controversies in depression","volume":"367","author":"Ebmeier KP","year":"2006","unstructured":"Ebmeier KP, Donaghey C, Steele JD. Recent developments and current controversies in depression. Lancet. 2006;367(9505):153\u201367.","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","article-title":"Classical psychedelics for the treatment of depression and anxiety: A systematic review","volume":"258","author":"Muttoni S","year":"2019","unstructured":"Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019;258:11\u201324.","journal-title":"J Affect Disord"},{"issue":"1","key":"ref5","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41398-021-01646-7","article-title":"Understanding complex functional wiring patterns in major depressive disorder through brain functional connectome","volume":"11","author":"Yang Z","year":"2021","unstructured":"Yang Z, Jian L, Qiu H, Zhang C, Cheng S, Ji J, et al. Understanding complex functional wiring patterns in major depressive disorder through brain functional connectome. Transl Psychiatry. 2021;11(1):526.","journal-title":"Transl Psychiatry"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jpsychires.2017.04.007","article-title":"Resting state brain network function in major depression - Depression symptomatology, antidepressant treatment effects, future research","volume":"92","author":"Brakowski J","year":"2017","unstructured":"Brakowski J, Spinelli S, D\u00f6rig N, Bosch OG, Manoliu A, Holtforth MG, et al. Resting state brain network function in major depression - Depression symptomatology, antidepressant treatment effects, future research. J Psychiatr Res. 2017;92:147\u201359.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41398-019-0467-9","article-title":"Connectome analysis of functional and structural hemispheric brain networks in major depressive disorder","volume":"9","author":"Jiang X","year":"2019","unstructured":"Jiang X, Shen Y, Yao J, Zhang L, Xu L, Feng R, et al. Connectome analysis of functional and structural hemispheric brain networks in major depressive disorder. Transl Psychiatry. 2019;9(1):136.","journal-title":"Transl Psychiatry"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1016\/j.jad.2020.05.053","article-title":"Functional connectivity of the prefrontal cortex and amygdala is related to depression status in major depressive disorder","volume":"274","author":"Zhang A","year":"2020","unstructured":"Zhang A, Yang C, Li G, Wang Y, Liu P, Liu Z, et al. Functional connectivity of the prefrontal cortex and amygdala is related to depression status in major depressive disorder. J Affect Disord. 2020;274:897\u2013902.","journal-title":"J Affect Disord"},{"key":"ref9","article-title":"Functional connectivity signatures of major depressive disorder: machine learning analysis of two multicenter neuroimaging studies","author":"Gallo S","year":"2023","unstructured":"Gallo S, El-Gazzar A, Zhutovsky P, Thomas RM, Javaheripour N, Li M et al. Functional connectivity signatures of major depressive disorder: machine learning analysis of two multicenter neuroimaging studies. Mol Psychiatry. 2023.","journal-title":"Mol Psychiatry"},{"issue":"11","key":"ref10","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/cns.12998","article-title":"A brain network model for depression: From symptom understanding to disease intervention","volume":"24","author":"Li BJ","year":"2018","unstructured":"Li BJ, Friston K, Mody M, Wang HN, Lu HB, Hu DW. A brain network model for depression: From symptom understanding to disease intervention. CNS Neurosci Ther. 2018;24(11):1004\u201319.","journal-title":"CNS Neurosci Ther"},{"issue":"21","key":"ref11","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph192114045","article-title":"Resting-State Functional Connectivity Impairment in Patients with Major Depressive Episode","volume":"19","author":"Stoyanov D","year":"2022","unstructured":"Stoyanov D, Khorev V, Paunova R, Kandilarova S, Simeonova D, Badarin A et al. Resting-State Functional Connectivity Impairment in Patients with Major Depressive Episode. Int J Environ Res Public Health. 2022;19(21).","journal-title":"Int J Environ Res Public Health"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuroimage.2019.05.060","article-title":"Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin","volume":"199","author":"Lord LD","year":"2019","unstructured":"Lord LD, Expert P, Atasoy S, Roseman L, Rapuano K, Lambiotte R, et al. Dynamical exploration of the repertoire of brain networks at rest is modulated by psilocybin. NeuroImage. 2019;199:127\u201342.","journal-title":"NeuroImage"},{"issue":"1","key":"ref13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.31887\/DCNS.2014.16.1\/sdelaloye","article-title":"Deep brain stimulation in the treatment of depression","volume":"16","author":"Delaloye S","year":"2014","unstructured":"Delaloye S, Holtzheimer PE. Deep brain stimulation in the treatment of depression. Dialogues Clin Neurosci. 2014;16(1):83\u201391.","journal-title":"Dialogues Clin Neurosci"},{"issue":"10128","key":"ref14","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1016\/S0140-6736(17)32802-7","article-title":"Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis","volume":"391","author":"Cipriani A","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357\u201366.","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"117913","DOI":"10.1016\/j.neuroimage.2021.117913","article-title":"Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm","volume":"232","author":"Spurny B","year":"2021","unstructured":"Spurny B, Vanicek T, Seiger R, Reed MB, Kl\u00f6bl M, Ritter V, et al. Effects of SSRI treatment on GABA and glutamate levels in an associative relearning paradigm. NeuroImage. 2021;232:117913.","journal-title":"NeuroImage"},{"issue":"13","key":"ref16","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1038\/s41386-018-0229-z","article-title":"Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans","volume":"43","author":"Skandali N","year":"2018","unstructured":"Skandali N, Rowe JB, Voon V, Deakin JB, Cardinal RN, Cormack F, et al. Dissociable effects of acute SSRI (escitalopram) on executive, learning and emotional functions in healthy humans. Neuropsychopharmacology. 2018;43(13):2645\u201351.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"ref17","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0197-2456(03)00112-0","article-title":"Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design","volume":"25","author":"Rush AJ","year":"2004","unstructured":"Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, et al. Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials. 2004;25(1):119\u201342.","journal-title":"Control Clin Trials"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1192\/bjp.180.5.396","article-title":"Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis","volume":"180","author":"Smith D","year":"2002","unstructured":"Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry. 2002;180:396\u2013404.","journal-title":"Br J Psychiatry"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1192\/bjp.178.3.234","article-title":"Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors","volume":"178","author":"Thase ME","year":"2001","unstructured":"Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234\u201341.","journal-title":"Br J Psychiatry"},{"issue":"1","key":"ref20","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3390\/ph3010019","article-title":"The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments","volume":"3","author":"Machado-Vieira R","year":"2010","unstructured":"Machado-Vieira R, Baumann J, Wheeler-Castillo C, Latov D, Henter ID, Salvadore G, et al. The Timing of Antidepressant Effects: A Comparison of Diverse Pharmacological and Somatic Treatments. Pharmaceuticals (Basel). 2010;3(1):19\u201341.","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"101809","DOI":"10.1016\/j.eclinm.2022.101809","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"Rotz R","year":"2023","unstructured":"von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, et al. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine. 2023;56:101809.","journal-title":"EClinicalMedicine"},{"issue":"18","key":"ref22","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression","volume":"387","author":"Goodwin GM","year":"2022","unstructured":"Goodwin GM, Aaronson ST, Alvarez O, Arden PC, Baker A, Bennett JC, et al. Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. N Engl J Med. 2022;387(18):1637\u201348.","journal-title":"N Engl J Med"},{"issue":"15","key":"ref23","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of Psilocybin versus Escitalopram for Depression","volume":"384","author":"Carhart-Harris R","year":"2021","unstructured":"Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. Trial of Psilocybin versus Escitalopram for Depression. N Engl J Med. 2021;384(15):1402\u201311.","journal-title":"N Engl J Med"},{"issue":"5","key":"ref24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial","volume":"78","author":"Davis AK","year":"2021","unstructured":"Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2021;78(5):481\u20139.","journal-title":"JAMA Psychiatry"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson M","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol"},{"issue":"11","key":"ref26","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1177\/0269881110382466","article-title":"Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies","volume":"25","author":"Studerus E","year":"2011","unstructured":"Studerus E, Kometer M, Hasler F, Vollenweider FX. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol. 2011;25(11):1434\u201352.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"ref27","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/02791072.2013.825034","article-title":"Experienced drug users assess the relative harms and benefits of drugs: a web-based survey","volume":"45","author":"Carhart-Harris RL","year":"2013","unstructured":"Carhart-Harris RL, Nutt DJ. Experienced drug users assess the relative harms and benefits of drugs: a web-based survey. J Psychoact Drugs. 2013;45(4):322\u20138.","journal-title":"J Psychoact Drugs"},{"issue":"10","key":"ref28","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41429-020-0311-8","article-title":"Psilocybin: from ancient magic to modern medicine","volume":"73","author":"Nichols DE","year":"2020","unstructured":"Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). 2020;73(10):679\u201386.","journal-title":"J Antibiot (Tokyo)"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1038\/s41591-022-01744-z","article-title":"Increased global integration in the brain after psilocybin therapy for depression","volume":"28","author":"Daws RE","year":"2022","unstructured":"Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, et al. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. 2022;28(4):844\u201351.","journal-title":"Nat Med"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"100906","DOI":"10.1016\/j.xcrm.2022.100906","article-title":"Is psilocybin an effective antidepressant and what is its Mechanism of action?","volume":"4","author":"Mann JJ","year":"2023","unstructured":"Mann JJ. Is psilocybin an effective antidepressant and what is its Mechanism of action? Cell Rep Med. 2023;4(1):100906.","journal-title":"Cell Rep Med"},{"issue":"1","key":"ref31","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1177\/2045125316676092","article-title":"Role of psilocybin in the treatment of depression","volume":"7","author":"Mahapatra A","year":"2017","unstructured":"Mahapatra A, Gupta R. Role of psilocybin in the treatment of depression. Ther Adv Psychopharmacol. 2017;7(1):54\u20136.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1038\/s41598-020-59282-y","article-title":"Emotions and brain function are altered up to one month after a single high dose of psilocybin","volume":"10","author":"Barrett FS","year":"2020","unstructured":"Barrett FS, Doss MK, Sepeda ND, Pekar JJ, Griffiths RR. Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep. 2020;10(1):2214.","journal-title":"Sci Rep"},{"issue":"10","key":"ref33","volume":"26","author":"Lowe H","year":"2021","unstructured":"Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A et al. The Therapeutic Potential of Psilocybin Molecules. 2021;26(10).","journal-title":"The Therapeutic Potential of Psilocybin Molecules"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1073\/pnas.1119598109","article-title":"Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin","volume":"109","author":"Carhart-Harris RL","year":"2012","unstructured":"Carhart-Harris RL, Erritzoe D, Williams T, Stone JM, Reed LJ, Colasanti A, et al. Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A. 2012;109(6):2138\u201343.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"ref35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/s41398-021-01706-y","article-title":"Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder","volume":"11","author":"Doss MK","year":"2021","unstructured":"Doss MK, Pova\u017ean M, Rosenberg MD, Sepeda ND, Davis AK, Finan PH, et al. Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. Transl Psychiatry. 2021;11(1):574.","journal-title":"Transl Psychiatry"},{"issue":"4","key":"ref36","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1038\/npp.2011.306","article-title":"Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review","volume":"37","author":"Undurraga J","year":"2012","unstructured":"Undurraga J, Baldessarini RJ. Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review. Neuropsychopharmacology. 2012;37(4):851\u201364.","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"ref37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/s41380-021-01397-3","article-title":"Placebo effects and neuromodulation for depression: a meta-analysis and evaluation of shared mechanisms","volume":"27","author":"Burke MJ","year":"2022","unstructured":"Burke MJ, Romanella SM, Mencarelli L, Greben R, Fox MD, Kaptchuk TJ, et al. Placebo effects and neuromodulation for depression: a meta-analysis and evaluation of shared mechanisms. Mol Psychiatry. 2022;27(3):1658\u201366.","journal-title":"Mol Psychiatry"},{"issue":"8","key":"ref38","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1017\/S0033291712001717","article-title":"Estimating remission from untreated major depression: a systematic review and meta-analysis","volume":"43","author":"Whiteford HA","year":"2013","unstructured":"Whiteford HA, Harris MG, McKeon G, Baxter A, Pennell C, Barendregt JJ, et al. Estimating remission from untreated major depression: a systematic review and meta-analysis. Psychol Med. 2013;43(8):1569\u201385.","journal-title":"Psychol Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jad.2021.09.046","article-title":"What is the short-term remission rate for people with untreated depression? A systematic review and meta-analysis","volume":"296","author":"Mekonen T","year":"2022","unstructured":"Mekonen T, Ford S, Chan GCK, Hides L, Connor JP, Leung J. What is the short-term remission rate for people with untreated depression? A systematic review and meta-analysis. J Affect Disord. 2022;296:17\u201325.","journal-title":"J Affect Disord"},{"issue":"9","key":"ref40","doi-asserted-by":"crossref","first-page":"e2125531","DOI":"10.1001\/jamanetworkopen.2021.25531","article-title":"Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults: A Systematic Review and Meta-analysis","volume":"4","author":"Jones BDM","year":"2021","unstructured":"Jones BDM, Razza LB, Weissman CR, Karbi J, Vine T, Mulsant LS, et al. Magnitude of the Placebo Response Across Treatment Modalities Used for Treatment-Resistant Depression in Adults: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(9):e2125531.","journal-title":"JAMA Netw Open"},{"issue":"9","key":"ref41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-Dose Psilocybin Treatment for Major Depressive Disorder","volume":"330","author":"Raison CL","year":"2023","unstructured":"Raison CL, Sanacora G, Woolley J, Heinzerling K, Dunlop BW, Brown RT, et al. Single-Dose Psilocybin Treatment for Major Depressive Disorder. JAMA. 2023;330(9):843.","journal-title":"JAMA"},{"issue":"16","key":"ref42","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao LX","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535\u20132544e4.","journal-title":"Neuron"},{"issue":"11","key":"ref43","doi-asserted-by":"crossref","first-page":"3170","DOI":"10.1016\/j.celrep.2018.05.022","article-title":"Psychedelics Promote Structural and Functional Neural Plasticity","volume":"23","author":"Ly C","year":"2018","unstructured":"Ly C, Greb AC, Cameron LP, Wong JM, Barragan EV, Wilson PC, et al. Psychedelics Promote Structural and Functional Neural Plasticity. Cell Rep. 2018;23(11):3170\u201382.","journal-title":"Cell Rep"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"724606","DOI":"10.3389\/fpsyt.2021.724606","article-title":"Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics","volume":"12","author":"Vos CMH","year":"2021","unstructured":"de Vos CMH, Mason NL, Kuypers KPC. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics. Front Psychiatry. 2021;12:724606.","journal-title":"Front Psychiatry"},{"issue":"1","key":"ref45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41386-022-01389-z","article-title":"Towards an understanding of psychedelic-induced neuroplasticity","volume":"48","author":"Calder AE","year":"2023","unstructured":"Calder AE, Hasler G. Towards an understanding of psychedelic-induced neuroplasticity. Neuropsychopharmacology. 2023;48(1):104\u201312.","journal-title":"Neuropsychopharmacology"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.3389\/fpsyg.2017.01657","article-title":"Dynamic Brains and the Changing Rules of Neuroplasticity: Implications for Learning and Recovery","volume":"8","author":"Voss P","year":"2017","unstructured":"Voss P, Thomas ME, Cisneros-Franco JM, de Villers-Sidani \u00c9. Dynamic Brains and the Changing Rules of Neuroplasticity: Implications for Learning and Recovery. Front Psychol. 2017;8:1657.","journal-title":"Front Psychol"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3389\/fncel.2019.00066","article-title":"The Impact of Studying Brain Plasticity","volume":"13","author":"Mateos-Aparicio P","year":"2019","unstructured":"Mateos-Aparicio P, Rodr\u00edguez-Moreno A. The Impact of Studying Brain Plasticity. Front Cell Neurosci. 2019;13:66.","journal-title":"Front Cell Neurosci"},{"year":"1949","author":"Hebb DO","key":"ref48","unstructured":"Hebb DO. The organization of behavior; a neuropsychological theory. The organization of behavior; a neuropsychological theory. Oxford, England: Wiley; 1949. 335, xix, 335\u2013xix p."},{"issue":"19","key":"ref49","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1113\/jphysiol.2012.232975","article-title":"The pharmacology of neuroplasticity induced by non-invasive brain stimulation: building models for the clinical use of CNS active drugs","volume":"590","author":"Nitsche MA","year":"2012","unstructured":"Nitsche MA, M\u00fcller-Dahlhaus F, Paulus W, Ziemann U. The pharmacology of neuroplasticity induced by non-invasive brain stimulation: building models for the clinical use of CNS active drugs. J Physiol. 2012;590(19):4641\u201362.","journal-title":"J Physiol"},{"issue":"2","key":"ref50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21020505","article-title":"Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease","volume":"21","author":"Crispino M","year":"2020","unstructured":"Crispino M, Volpicelli F, Perrone-Capano C. Role of the Serotonin Receptor 7 in Brain Plasticity: From Development to Disease. Int J Mol Sci. 2020;21(2).","journal-title":"Int J Mol Sci"},{"issue":"2","key":"ref51","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020835","article-title":"A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain","volume":"22","author":"Raval NR","year":"2021","unstructured":"Raval NR, Johansen A, Donovan LL, Ros NF, Ozenne B, Hansen HD et al. A Single Dose of Psilocybin Increases Synaptic Density and Decreases 5-HT2A Receptor Density in the Pig Brain. Int J Mol Sci. 2021;22(2).","journal-title":"Int J Mol Sci"},{"issue":"7","key":"ref52","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1038\/s41386-019-0360-5","article-title":"Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels","volume":"44","author":"Madsen MK","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, et al. Correction: Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1336\u20137.","journal-title":"Neuropsychopharmacology"},{"issue":"12","key":"ref53","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41386-020-0718-8","article-title":"Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin","volume":"45","author":"Mason NL","year":"2020","unstructured":"Mason NL, Kuypers KPC, M\u00fcller F, Reckweg J, Tse DHY, Toennes SW, et al. Me, myself, bye: regional alterations in glutamate and the experience of ego dissolution with psilocybin. Neuropsychopharmacology. 2020;45(12):2003\u201311.","journal-title":"Neuropsychopharmacology"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"116980","DOI":"10.1016\/j.neuroimage.2020.116980","article-title":"Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention","volume":"218","author":"Barrett FS","year":"2020","unstructured":"Barrett FS, Krimmel SR, Griffiths RR, Seminowicz DA, Mathur BN. Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. NeuroImage. 2020;218:116980.","journal-title":"NeuroImage"},{"year":"1979","author":"Vargas MV","key":"ref55","unstructured":"Vargas MV, Dunlap LE, Dong C, Carter SJ, Tombari RJ, Jami SA et al. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Science (1979). 2023;379(6633):700\u20136."},{"issue":"6","key":"ref56","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1038\/s41593-023-01316-5","article-title":"Psychedelics promote plasticity by directly binding to BDNF receptor TrkB","volume":"26","author":"Moliner R","year":"2023","unstructured":"Moliner R, Girych M, Brunello CA, Kovaleva V, Biojone C, Enkavi G, et al. Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nat Neurosci. 2023;26(6):1032\u201341.","journal-title":"Nat Neurosci"},{"issue":"16","key":"ref57","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1016\/j.neuron.2021.06.008","article-title":"Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo","volume":"109","author":"Shao LX","year":"2021","unstructured":"Shao LX, Liao C, Gregg I, Davoudian PA, Savalia NK, Delagarza K, et al. Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron. 2021;109(16):2535\u20132544e4.","journal-title":"Neuron"},{"issue":"5","key":"ref58","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1176\/appi.ajp.20220835","article-title":"Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects","volume":"180","author":"Rosenblat JD","year":"2023","unstructured":"Rosenblat JD, Leon-Carlyle M, Ali S, Husain MI, McIntyre RS. Antidepressant Effects of Psilocybin in the Absence of Psychedelic Effects. Am J Psychiatry. 2023;180(5):395\u20136.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.jneumeth.2008.04.012","article-title":"An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF","volume":"172","author":"Zou QH","year":"2008","unstructured":"Zou QH, Zhu CZ, Yang Y, Zuo XN, Long XY, Cao QJ, et al. An improved approach to detection of amplitude of low-frequency fluctuation (ALFF) for resting-state fMRI: fractional ALFF. J Neurosci Methods. 2008;172(1):137\u201341.","journal-title":"J Neurosci Methods"},{"issue":"1","key":"ref60","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/mrm.25197","article-title":"Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia","volume":"73","author":"Alsop DC","year":"2015","unstructured":"Alsop DC, Detre JA, Golay X, G\u00fcnther M, Hendrikse J, Hernandez-Garcia L, et al. Recommended implementation of arterial spin-labeled perfusion MRI for clinical applications: A consensus of the ISMRM perfusion study group and the European consortium for ASL in dementia. Magn Reson Med. 2015;73(1):102\u201316.","journal-title":"Magn Reson Med"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"118923","DOI":"10.1016\/j.neuroimage.2022.118923","article-title":"Hemodynamic and metabolic correspondence of resting-state voxel-based physiological metrics in healthy adults","volume":"250","author":"Deng S","year":"2022","unstructured":"Deng S, Franklin CG, O\u2019Boyle M, Zhang W, Heyl BL, Jerabek PA, et al. Hemodynamic and metabolic correspondence of resting-state voxel-based physiological metrics in healthy adults. NeuroImage. 2022;250:118923.","journal-title":"NeuroImage"},{"issue":"1","key":"ref62","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/jcbfm.2009.204","article-title":"Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion","volume":"30","author":"Bokkers RPH","year":"2010","unstructured":"Bokkers RPH, Bremmer JP, van Berckel BNM, Lammertsma AA, Hendrikse J, Pluim JPW, et al. Arterial spin labeling perfusion MRI at multiple delay times: a correlative study with H(2)(15)O positron emission tomography in patients with symptomatic carotid artery occlusion. J Cereb Blood Flow Metab. 2010;30(1):222\u20139.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"3","key":"ref63","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/bdi.13288","article-title":"Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement","volume":"25","author":"Kim WSH","year":"2023","unstructured":"Kim WSH, Dimick MK, Omrin D, Mitchell RHB, Riegert D, Levitt A, et al. Proof-of-concept randomized controlled trial of single-session nitrous oxide treatment for refractory bipolar depression: Focus on cerebrovascular target engagement. Bipolar Disord. 2023;25(3):221\u201332.","journal-title":"Bipolar Disord"},{"issue":"10","key":"ref64","doi-asserted-by":"crossref","first-page":"e0164112","DOI":"10.1371\/journal.pone.0164112","article-title":"Mapping Long-Term Functional Changes in Cerebral Blood Flow by Arterial Spin Labeling","volume":"11","author":"Ssali T","year":"2016","unstructured":"Ssali T, Anazodo UC, Bureau Y, MacIntosh BJ, G\u00fcnther M, St Lawrence K. Mapping Long-Term Functional Changes in Cerebral Blood Flow by Arterial Spin Labeling. PLoS ONE. 2016;11(10):e0164112.","journal-title":"PLoS ONE"},{"issue":"1","key":"ref65","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.neuroimage.2009.07.068","article-title":"all named co-authors of the QUASAR test-retest study. The QUASAR reproducibility study, Part II: Results from a multi-center Arterial Spin Labeling test-retest study","volume":"49","author":"Petersen ET","year":"2010","unstructured":"Petersen ET, Mouridsen K, Golay X. all named co-authors of the QUASAR test-retest study. The QUASAR reproducibility study, Part II: Results from a multi-center Arterial Spin Labeling test-retest study. NeuroImage. 2010;49(1):104\u201313.","journal-title":"NeuroImage"},{"issue":"10","key":"ref66","doi-asserted-by":"crossref","first-page":"384","DOI":"10.4329\/wjr.v2.i10.384","article-title":"Arterial spin labeling in neuroimaging","volume":"2","author":"Petcharunpaisan S","year":"2010","unstructured":"Petcharunpaisan S, Ramalho J, Castillo M. Arterial spin labeling in neuroimaging. World J Radiol. 2010;2(10):384\u201398.","journal-title":"World J Radiol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.euroneuro.2020.09.633","article-title":"Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis","volume":"41","author":"Shi Y","year":"2020","unstructured":"Shi Y, Luan D, Song R, Zhang Z. Value of peripheral neurotrophin levels for the diagnosis of depression and response to treatment: A systematic review and meta-analysis. Eur Neuropsychopharmacol. 2020;41:40\u201351.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"7","key":"ref68","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1177\/02698811221092508","article-title":"Neural mechanisms underlying psilocybin\u2019s therapeutic potential - the need for preclinical in vivo electrophysiology","volume":"36","author":"Smausz R","year":"2022","unstructured":"Smausz R, Neill J, Gigg J. Neural mechanisms underlying psilocybin\u2019s therapeutic potential - the need for preclinical in vivo electrophysiology. J Psychopharmacol. 2022;36(7):781\u201393.","journal-title":"J Psychopharmacol"},{"issue":"4","key":"ref69","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects","volume":"111","author":"Becker AM","year":"2022","unstructured":"Becker AM, Holze F, Grandinetti T, Klaiber A, Toedtli VE, Kolaczynska KE, et al. Acute Effects of Psilocybin After Escitalopram or Placebo Pretreatment in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Subjects. Clin Pharmacol Ther. 2022;111(4):886\u201395.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"ref70","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031616","article-title":"C-Reactive Protein as a Biomarker for Major Depressive Disorder?","volume":"23","author":"Orsolini L","year":"2022","unstructured":"Orsolini L, Pompili S, Tempia Valenta S, Salvi V, Volpe U. C-Reactive Protein as a Biomarker for Major Depressive Disorder? Int J Mol Sci. 2022;23(3).","journal-title":"Int J Mol Sci"},{"issue":"6","key":"ref71","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/s41380-018-0096-3","article-title":"What does plasma CRP tell us about peripheral and central inflammation in depression?","volume":"25","author":"Felger JC","year":"2020","unstructured":"Felger JC, Haroon E, Patel TA, Goldsmith DR, Wommack EC, Woolwine BJ, et al. What does plasma CRP tell us about peripheral and central inflammation in depression? Mol Psychiatry. 2020;25(6):1301\u201311.","journal-title":"Mol Psychiatry"},{"issue":"1","key":"ref72","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00702-018-1844-x","article-title":"Blood-based biomarkers predicting response to antidepressants","volume":"126","author":"Busch Y","year":"2019","unstructured":"Busch Y, Menke A. Blood-based biomarkers predicting response to antidepressants. J Neural Transm (Vienna). 2019;126(1):47\u201363.","journal-title":"J Neural Transm (Vienna)"},{"issue":"7","key":"ref73","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1038\/s41372-019-0363-4","article-title":"Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis","volume":"39","author":"Eschborn S","year":"2019","unstructured":"Eschborn S, Weitkamp JH. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. J Perinatol. 2019;39(7):893\u2013903.","journal-title":"J Perinatol"},{"issue":"5","key":"ref74","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1111\/j.1440-1711.2000.t01-11-.x","article-title":"Exercise and cytokines","volume":"78","author":"Pedersen BK","year":"2000","unstructured":"Pedersen BK. Exercise and cytokines. Immunol Cell Biol. 2000;78(5):532\u20135.","journal-title":"Immunol Cell Biol"},{"issue":"6","key":"ref75","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/da.22217","article-title":"Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV","volume":"31","author":"Uher R","year":"2014","unstructured":"Uher R, Payne JL, Pavlova B, Perlis RH. Major depressive disorder in DSM-5: implications for clinical practice and research of changes from DSM-IV. Depress Anxiety. 2014;31(6):459\u201371.","journal-title":"Depress Anxiety"},{"issue":"24","key":"ref76","first-page":"2711","volume":"139","author":"Giudicessi JR","year":"2019","unstructured":"Giudicessi JR, Noseworthy PA, Ackerman MJ. The QT Interval Circulation. 2019;139(24):2711\u20133.","journal-title":"The QT Interval Circulation"},{"issue":"2","key":"ref77","first-page":"e21944","article-title":"Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review","volume":"14","author":"Ziff S","year":"2022","unstructured":"Ziff S, Stern B, Lewis G, Majeed M, Gorantla VR. Analysis of Psilocybin-Assisted Therapy in Medicine: A Narrative Review. Cureus. 2022;14(2):e21944.","journal-title":"Cureus"},{"issue":"1","key":"ref78","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob CS","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"12","key":"ref79","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross S","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"ref80","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris RL","year":"2016","unstructured":"Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry. 2016;3(7):619\u201327.","journal-title":"Lancet Psychiatry"},{"issue":"3","key":"ref81","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.yrtph.2011.01.006","article-title":"Harm potential of magic mushroom use: a review","volume":"59","author":"Amsterdam J","year":"2011","unstructured":"van Amsterdam J, Opperhuizen A, van den Brink W. Harm potential of magic mushroom use: a review. Regul Toxicol Pharmacol. 2011;59(3):423\u20139.","journal-title":"Regul Toxicol Pharmacol"},{"issue":"6","key":"ref82","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson M","year":"2008","unstructured":"Johnson M, Richards W, Griffiths R. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"ref83","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1177\/0269881118780713","article-title":"High dose psilocybin is associated with positive subjective effects in healthy volunteers","volume":"32","author":"Nicholas CR","year":"2018","unstructured":"Nicholas CR, Henriquez KM, Gassman MC, Cooper KM, Muller D, Hetzel S, et al. High dose psilocybin is associated with positive subjective effects in healthy volunteers. J Psychopharmacol. 2018;32(7):770\u20138.","journal-title":"J Psychopharmacol"},{"issue":"3","key":"ref84","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1002\/mpr.1388","article-title":"The structure of the Montgomery-\u00c5sberg depression rating scale over the course of treatment for depression","volume":"22","author":"Quilty LC","year":"2013","unstructured":"Quilty LC, Robinson JJ, Rolland JP, Fruyt F, De, Rouillon F, Bagby RM. The structure of the Montgomery-\u00c5sberg depression rating scale over the course of treatment for depression. Int J Methods Psychiatr Res. 2013;22(3):175\u201384.","journal-title":"Int J Methods Psychiatr Res"},{"issue":"3","key":"ref85","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/YIC.0b013e3282f948f5","article-title":"The GRID-HAMD: standardization of the Hamilton Depression Rating Scale","volume":"23","author":"Williams JBW","year":"2008","unstructured":"Williams JBW, Kobak KA, Bech P, Engelhardt N, Evans K, Lipsitz J, et al. The GRID-HAMD: standardization of the Hamilton Depression Rating Scale. Int Clin Psychopharmacol. 2008;23(3):120\u20139.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"ref86","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/YIC.0b013e3283277614","article-title":"Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning","volume":"24","author":"Trivedi MH","year":"2009","unstructured":"Trivedi MH, Corey-Lisle PK, Guo Z, Lennox RD, Pikalov A, Kim E. Remission, response without remission, and nonresponse in major depressive disorder: impact on functioning. Int Clin Psychopharmacol. 2009;24(3):133\u20138.","journal-title":"Int Clin Psychopharmacol"},{"issue":"9","key":"ref87","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamapsychiatry.2019.1189","article-title":"Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial","volume":"76","author":"Daly EJ","year":"2019","unstructured":"Daly EJ, Trivedi MH, Janik A, Li H, Zhang Y, Li X, et al. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2019;76(9):893\u2013903.","journal-title":"JAMA Psychiatry"},{"issue":"9","key":"ref88","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke K","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001;16(9):606\u201313.","journal-title":"J Gen Intern Med"},{"issue":"5","key":"ref89","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0006-3223(02)01866-8","article-title":"The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression","volume":"54","author":"Rush AJ","year":"2003","unstructured":"Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573\u201383.","journal-title":"Biol Psychiatry"},{"issue":"7","key":"ref90","first-page":"28","article-title":"The clinical global impressions scale: applying a research tool in clinical practice","volume":"4","author":"Busner J","year":"2007","unstructured":"Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28\u201337.","journal-title":"Psychiatry (Edgmont)"},{"issue":"5","key":"ref91","first-page":"CD3","article-title":"Calculated Decisions: Columbia-Suicide Severity Rating Scale (C-SSRS)","volume":"21","author":"Salvi J","year":"2019","unstructured":"Salvi J. Calculated Decisions: Columbia-Suicide Severity Rating Scale (C-SSRS). Emerg Med Pract. 2019;21(5):CD3\u20134.","journal-title":"Emerg Med Pract"},{"issue":"2","key":"ref92","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.psychres.2013.07.001","article-title":"The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression","volume":"210","author":"Zanello A","year":"2013","unstructured":"Zanello A, Berthoud L, Ventura J, Merlo MCG. The Brief Psychiatric Rating Scale (version 4.0) factorial structure and its sensitivity in the treatment of outpatients with unipolar depression. Psychiatry Res. 2013;210(2):626\u201333.","journal-title":"Psychiatry Res"},{"issue":"2","key":"ref93","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/YIC.0b013e3282f2b4d6","article-title":"Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale","volume":"23","author":"Sheehan KH","year":"2008","unstructured":"Sheehan KH, Sheehan DV. Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol. 2008;23(2):70\u201383.","journal-title":"Int Clin Psychopharmacol"},{"issue":"3","key":"ref94","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1159\/000376585","article-title":"The WHO-5 Well-Being Index: a systematic review of the literature","volume":"84","author":"Topp CW","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P. The WHO-5 Well-Being Index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167\u201376.","journal-title":"Psychother Psychosom"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.2147\/JPR.S207870","article-title":"The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy","volume":"12","author":"Wawrzyniak KM","year":"2019","unstructured":"Wawrzyniak KM, Finkelman M, Schatman ME, Kulich RJ, Weed VF, Myrta E, et al. The World Health Organization Disability Assessment Schedule-2.0 (WHODAS 2.0) in a chronic pain population being considered for chronic opioid therapy. J Pain Res. 2019;12:1855\u201362.","journal-title":"J Pain Res"},{"key":"ref96","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.3389\/fpsyg.2019.01713","article-title":"Psychometric Properties of the General Anxiety Disorder 7-Item (GAD-7) Scale in a Heterogeneous Psychiatric Sample","volume":"10","author":"Johnson SU","year":"2019","unstructured":"Johnson SU, Ulvenes PG, \u00d8ktedalen T, Hoffart A. Psychometric Properties of the General Anxiety Disorder 7-Item (GAD-7) Scale in a Heterogeneous Psychiatric Sample. Front Psychol. 2019;10:1713.","journal-title":"Front Psychol"},{"issue":"1","key":"ref97","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1192\/bjp.167.1.99","article-title":"A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale","volume":"167","author":"Snaith RP","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167(1):99\u2013103.","journal-title":"Br J Psychiatry"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.119","article-title":"A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions","volume":"282","author":"Rodrigues NB","year":"2021","unstructured":"Rodrigues NB, McIntyre RS, Lipsitz O, Lee Y, Cha DS, Shekotikhina M, et al. A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions. J Affect Disord. 2021;282:160\u20134.","journal-title":"J Affect Disord"},{"issue":"6","key":"ref99","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1177\/1740774512465064","article-title":"Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials","volume":"9","author":"Younger J","year":"2012","unstructured":"Younger J, Gandhi V, Hubbard E, Mackey S. Development of the Stanford Expectations of Treatment Scale (SETS): a tool for measuring patient outcome expectancy in clinical trials. Clin Trials. 2012;9(6):767\u201376.","journal-title":"Clin Trials"},{"issue":"4","key":"ref100","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","article-title":"The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment","volume":"53","author":"Nasreddine ZS","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13195-015-0164-8","article-title":"Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software","volume":"7","author":"Akter S","year":"2015","unstructured":"Akter S, Hassan MR, Shahriar M, Akter N, Abbas MG, Bhuiyan MA. Cognitive impact after short-term exposure to different proton pump inhibitors: assessment using CANTAB software. Alzheimers Res Ther. 2015;7:79.","journal-title":"Alzheimers Res Ther"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1007\/978-0-387-79948-3_1127","volume-title":"Encyclopedia of Clinical Neuropsychology","author":"Belkonen S","year":"2011","unstructured":"Belkonen S. Hopkins Verbal Learning Test. Encyclopedia of Clinical Neuropsychology. New York, NY: Springer New York; 2011. 1264\u20135."},{"issue":"4","key":"ref103","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.biopsych.2007.05.033","article-title":"Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder","volume":"63","author":"Grimm S","year":"2008","unstructured":"Grimm S, Beck J, Schuepbach D, Hell D, Boesiger P, Bermpohl F, et al. Imbalance between left and right dorsolateral prefrontal cortex in major depression is linked to negative emotional judgment: an fMRI study in severe major depressive disorder. Biol Psychiatry. 2008;63(4):369\u201376.","journal-title":"Biol Psychiatry"},{"issue":"1","key":"ref104","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41398-020-01036-5","article-title":"Common and distinct patterns of intrinsic brain activity alterations in major depression and bipolar disorder: voxel-based meta-analysis","volume":"10","author":"Gong J","year":"2020","unstructured":"Gong J, Wang J, Qiu S, Chen P, Luo Z, Wang J, et al. Common and distinct patterns of intrinsic brain activity alterations in major depression and bipolar disorder: voxel-based meta-analysis. Transl Psychiatry. 2020;10(1):353.","journal-title":"Transl Psychiatry"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.jad.2019.11.009","article-title":"Proof-of-concept study of a multi-gene risk score in adolescent bipolar disorder","volume":"262","author":"Dimick MK","year":"2020","unstructured":"Dimick MK, Cazes J, Fiksenbaum LM, Zai CC, Tampakeras M, Freeman N, et al. Proof-of-concept study of a multi-gene risk score in adolescent bipolar disorder. J Affect Disord. 2020;262:211\u201322.","journal-title":"J Affect Disord"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.neuroimage.2017.07.020","article-title":"Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow","volume":"159","author":"Lewis CR","year":"2017","unstructured":"Lewis CR, Preller KH, Kraehenmann R, Michels L, Staempfli P, Vollenweider FX. Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. NeuroImage. 2017;159:70\u20138.","journal-title":"NeuroImage"},{"issue":"1","key":"ref107","doi-asserted-by":"crossref","first-page":"13187","DOI":"10.1038\/s41598-017-13282-7","article-title":"Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms","volume":"7","author":"Carhart-Harris RL","year":"2017","unstructured":"Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, et al. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Sci Rep. 2017;7(1):13187.","journal-title":"Sci Rep"},{"issue":"12","key":"ref108","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial","volume":"30","author":"Griffiths RR","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"1040217","DOI":"10.3389\/fpsyt.2022.1040217","article-title":"Therapeutic use of psilocybin: Practical considerations for dosing and administration","volume":"13","author":"MacCallum CA","year":"2022","unstructured":"MacCallum CA, Lo LA, Pistawka CA, Deol JK. Therapeutic use of psilocybin: Practical considerations for dosing and administration. Front Psychiatry. 2022;13:1040217.","journal-title":"Front Psychiatry"},{"issue":"6","key":"ref110","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson KR","year":"1996","unstructured":"Bonson KR, Buckholtz JW, Murphy DL. Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans. Neuropsychopharmacology. 1996;14(6):425\u201336.","journal-title":"Neuropsychopharmacology"},{"issue":"7","key":"ref111","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1177\/02698811231179910","article-title":"Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use","volume":"37","author":"Gukasyan N","year":"2023","unstructured":"Gukasyan N, Griffiths RR, Yaden DB, Antoine DG, Nayak SM. Attenuation of psilocybin mushroom effects during and after SSRI\/SNRI antidepressant use. J Psychopharmacol. 2023;37(7):707\u201316.","journal-title":"J Psychopharmacol"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3474764\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3474764\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,28]],"date-time":"2023-12-28T12:19:36Z","timestamp":1703765976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-3474764\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,28]]},"references-count":111,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-3474764\/v1","relation":{},"subject":[],"published":{"date-parts":[[2023,12,28]]},"subtype":"preprint"}}